Opal Capital’s Nektar Therapeutics NKTR Stock Holding History

Opal Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,948	Closed	-$220K	–	195
2025 Q4	$220K	Buy	+5,948	New	+$333K	0.06%	165

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Opal Capital's NKTR Position: Q1 2026 in Review

Opal Capital sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 5,948 shares — an estimated $220K sold.

Opal Capital first reported a position in NKTR in Q4 2025 and held it in 1 quarter. The position peaked at $220K in Q4 2025. 216 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Opal Capital reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
Opal Capital sold 5,948 Nektar Therapeutics shares in Q1 2026, an estimated $220K.
Opal Capital first reported a position in Nektar Therapeutics in Q4 2025 and held it in 1 quarter.
Opal Capital's Nektar Therapeutics position peaked at $220K in Q4 2025.
216 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Opal Capital's 13F filing for Q1 2026, filed 18 May 2026.